Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial

Philippe L. Bedard,^{1*} Seock-Ah Im,² Elena Elimova,¹ SY Rha,³ Rachel Goodwin,⁴ Cristiano Ferrario,⁵ Keun-Wook Lee,⁶ Diana Hanna,⁷ Funda Meric-Bernstam,⁸ Jose Mayordomo,⁹ Murali Beeram,¹⁰ Erika Hamilton,¹¹ Jorge Chaves,¹² Melody Cobleigh,¹³ Tony Mwatha,¹⁴ Joseph Woolery,¹⁴ Do-Youn Oh² ¹Princess Margaret Cancer Centre, Toronto, ON, Canada; ²Seoul National University College of Medicine, Seoul, Korea; ⁴University of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea; ⁷USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; ⁹University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁰The START Center for Cancer Center, Los Angeles, CA, USA; ¹¹Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; ¹²Northwest Medical Specialists, Tacoma, WA, USA; ¹³Rush University Medical Center, Chicago, IL, USA; ¹⁴Zymeworks Inc., Vancouver, BC, Canada.

BACKGROUND


- After progression with other available HER2-targeted therapies, the treatment for patients with advanced HER2-positive BC is generally a regimen comprised of a HER2-targeted monoclonal antibody (e.g., trastuzumab) combined with a single chemotherapeutic agent¹ - Based on a recent phase 3 trial of previously treated patients (1-3 prior therapies) the overall response rate with such therapy is < 25% with median progression-free survival (PFS) < 6 months, and the median overall survival for these patients is < 2 years²
- Zanidatamab (also known as ZW25) is a humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane domain (ECD4) and the dimerization domain (ECD2) of HER2 (Figure 1)³
- Zanidatamab's unique binding properties result in:³
- Receptor clustering, internalization, and downregulation
- Inhibition of growth factor-dependent and -independent tumor cell proliferation Antibody-dependent cellular cytotoxicity and phagocytosis, and complement-dependent cytotoxicity
- In ongoing phase 1 and 2 trials, zanidatamab monotherapy has been well tolerated with durable responses in subjects with heavily pretreated metastatic HER2-positive BC,⁴ and HER2expressing cancers, including gastroesophageal adenocarcinoma and biliary tract cancer⁵⁻⁷

METHODS

Trial Design


- In Part 3 of this ongoing phase 1 trial (NCT02892123),⁸ we evaluated the safety and antitumor activity of zanidatamab in combination with chemotherapy in patients with HER2-positive metastatic BC (monotherapy BC data from Parts 1 and 2 previously reported⁴)
- Zanidatamab dosing was based on subject weight
- To prevent or minimize infusion-related reactions, all subjects received prophylactic treatment with acetaminophen, diphenhydramine, and corticosteroid prior to administration of zanidatamab

Figure 2: ZWI-ZW25-101 Trial Design for Patients with HER2-positive BC in Part 3



CBR = clinical benefit rate; CR = complete response; DCR = disease control rate; DOR = duration of response; ECOG PS = Eastern Cooperative Oncology Group performance status; ORR = objective response rate; PD = progressive disease; PFS = progression-free survival; PR = partial response; SD = stable disease. ^aVinorelbine: vinorelbine 25 mg/m² QW on days 1, 8, 15, 22. ^bCapecitabine: with zanidatamab 20 mg/kg Q2W, 2000 mg twice daily for 7 days in weeks 1 and 3 or 1000 mg/m² twice daily on days 1-14 on a 21-day cycle; with zanidatamab 30 mg/kg Q3W, 1000 mg/m² twice daily on days 1-14 on a 21-day cycle. ^cPaclitaxel: paclitaxel 80 mg/m² QW for weeks 1-3. ^dORR was defined as the percentage of subjects who have \geq 1 overall tumor responses of CR/PR by RECIST v1.1. °CBR was defined as a best overall response of CR/PR, or SD or non-CR/non-PD \geq 24 weeks. ^fDCR was defined as a best response of CR, PR, or SD. BDOR was defined as time from first confirmed objective response until PD or death in subjects who had a CR/PR followed by \geq 1 additional response assessment. ^hPFS was defined as time from first dose of zanidatamab to the date of documented disease progression per RECIST v1.1, clinical progression, or death from any cause.

Figure 1: Unique Binding Properties of Zanidatamab



nidatamab antibodie

HR status, n (9 HR positive HR negativ Not report Prior history c Prior systemic **Patients with** Trastuzum

treatment

	Zanidatamab + Vinorelbine (n = 12)		Zanidatamab + Capecitabine (n = 8)		Zanidatamab + Paclitaxel (n = 4)		Total (N = 24)	
	Any	Grade	Any	Grade	Any	Grade	Any	Grade
	Grade	≥ 3	Grade	≥ 3	Grade	≥ 3	Grade	≥ 3
TRAE,ª n (%)	11 (92)	7 (58)	8 (100)	3 (38)	3 (75)	3 (75)	22 (92)	13 (54)
Treatment-related SAE	0	0	0	0	0	0	0	0
TRAEs leading to treatment discontinuation ^b	1 (8)	1 (8)	1 (13)	0	0	0	2 (8)	1 (4)
TRAEs occurring in $\ge 20\%$ of subjects and/or Grade ≥ 3 TRAEs in > 1 subject								
Diarrhea	10 (83)	1 (8)	5 (63)	1 (13)	2 (50)	0	17 (71)	2 (8)
Nausea	3 (25)	0	5 (63)	0	0	0	8 (33)	0
Stomatitis	2 (17)	0	4 (50)	0	1 (25)	0	7 (29)	0
Fatigue	3 (25)	0	3 (38)	0	0	0	6 (25)	0
Peripheral neuropathy	1(8)	0	2 (25)	0	3 (75)	1 (25)	6 (25)	1 (4)
PPE	0	0	6 (75)	0	0	0	6 (25)	0
Neutrophil count decreased	6 (50)	6 (50)	0	0	0	0	6 (25)	6 (25)
Neutropenia	2 (17)	1 (8)	0	0	2 (50)	2 (50)	4 (17)	3 (13)
AESI in any subject								
Infusion-related reaction	1 (8)	0	1 (13)	0	1 (25)	0	3 (13)	0
Cardiac events ^c	1 (8)	0	1 (13)	0	0	0	2 (8)	0
Pneumonitis	1 (8)	0	0	0	0	0	1 (4)	0

Data were extracted on October 12, 2021 from an unlocked database. • Of 24 subjects with HER2-positive BC enrolled in Part 3 of this trial, 10 (42%) continue on

• 13 (54%) subjects have discontinued treatment due to disease progression and 1 (4%) due to an adverse event (AE; treatment-related grade 3 diarrhea)

Table 1: Demographics and Baseline Characteristics

	Subjects (N = 24)
Median age (range), years	55 (37–72)
Female sex, n (%)	24 (100)
Race, n (%)	
Asian	15 (63)
White	9 (38)
ECOG PS, n (%)	
0	12 (50)
1	12 (50)
HER2 positive, ^a n (%)	24 (100)
HR status, n (%)	
HR positive ^b	10 (42)
HR negative	10 (42)
Not reported	4 (17)
Prior history of brain metastases, n (%)	9 (38)
Prior systemic cancer regimens in the metastatic setting, median (range)	2.0 (0-6)
Patients with prior HER2-targeted therapies, n (%)	23 (96) ^c
Trastuzumab	23 (96)
T-DM1	23 (96)
Pertuzumab ^d	20 (83)
Lapatinib	5 (21)
Neratinib	2 (8)
Tucatinib/placebo ^e	2 (8)
Margetuximab	1 (4)
Tucatinib	1 (4)


ECOG PS = Eastern Cooperative Oncology Group performance status; ER = estrogen receptor; HR = hormone receptor ^aAll subjects had HER2 status centrally confirmed. ^bAll subjects had ER-positive tumors. ^cAt time of data extraction, 1 subject was missing information on prior HER2-targeted therapies. ^dThree subjects did not have access to pertuzumab and were allowed to enroll after consultation with the trial sponsor per protocol. Possibly treated with investigational tucatinib.

- Safety was formally assessed by the Safety Monitoring Committee (SMC) after the first 6 subjects were enrolled to each cohort
- Among the first 6 subjects dosed in the vinorelbine (25 mg/m² weekly) cohort, 2 subjects had chemotherapy dose reductions due to grade 3-4 neutrophil count decreased in Cycle 1:
- 2 events led to vinorelbine dose reduction in 2 subjects - The SMC recommended vinorelbine dosing be altered from continuous weekly dosing to dosing on
- days 1 and 15 of a 28-day cycle - 1 subject (of 6) experienced grade 4 neutrophil count decreased (Cycle 1, Day 15) in the vinorelbine cohort after this dosing schedule modification
- 2 (8%) subjects experienced 3 serious AEs, none related to trial treatment:
- 1 subject experienced upper respiratory infection and pneumonitis, and 1 subject experienced pleural effusion

disease (N = 22)


Median follow-up time was 7.1 months

Figure 3: Best Reduction in Target Lesions



pertuzumab; T = trastuzumab; Trt = treatment.

Figure 4: Treatment Duration



SOD = sum of diamete

RESULTS

Efficacy

• The HER2-positive BC efficacy-evaluable population was defined as subjects with measurable





Figure 5: Progression-free Survival in All Subj



NE = not estimable; PFS = progression-free survival

Table 3: Response Rates and DOR

HER2-positive Subjects	Zani + Vino (n = 11)	Zani + Cape (n = 7)	Zani + Pac (n = 4)	Total (N = 22)	
	27.3	42.9	50.0	36.4	
cORR, % (95% CI)	(6.0, 61.0)	(9.9 <i>,</i> 81.6)	(6.8, 93.2)	(13.9, 54.9)	
PR, n (%)	3 (27.3)	3 (42.9)	2 (50)	8 (36.4)	
SD, n (%)	6 (54.5)	4 (57.1)	1 (25)	11 (50)	
PD, n (%)	2 (18.2)	0	1 (25)	3 (13.6)	
	27.3	85.7	75.0	54.5 ^a	
CBR, ^a % (95% CI)	(6.0, 61.0)	(42.1, 99.6)	(19.4, 99.4)	(32.2, 75.6)	
	81.8	100	75.0	86.4	
DCR, % (95% CI)	(48.2, 97.7)	(59.0, 100)	(19.4, 99.4)	(65.1 <i>,</i> 97.1)	
DOR range, months	1.6–3.7	3.6–16.7+	18.4–22.1+	1.6-22.1+	

Cape = capecitabine; CBR = clinical benefit rate; cORR = confirmed objective response rate; DCR = disease control rate; DOR = duration of response; Pac = paclitaxel; PD = progressive disease PR = partial response; SD = stable disease; Vino = vinorelbine; Zani = zanidatamab. ^aDoes not include 2 subjects currently on trial treatment < 6 months with a response of SD.

CONCLUSIONS

- Zanidatamab in combination with chemotherapy demonstrates encouraging antitumor activity in heavily pretreated subjects with HER2-positive BC: – 36.4% confirmed objective response rate (cORR) and a median progression-free survival (PFS) of
- 7.3 months across all treatment regimens compare favorably to historical data² - 4 of 8 responses are ongoing with response duration range of 1.8+ to 22.1+ months
- Zanidatamab in combination with single agent chemotherapy is well tolerated: - Diarrhea is the most frequent treatment-related AE observed across regimens and is manageable, the majority (> 90%) being low grade
- Few infusion-related reactions or cardiac events were observed, none severe (grade \geq 3) novel therapeutic option for treatment of patients with HER2-positive locally advanced or
- These data support further investigation of zanidatamab + single agent chemotherapy as a metastatic breast cancer after \geq 3 lines of prior therapy
- The capecitabine and vinorelbine cohorts continue to enroll, evaluating the combination of zanidatamab and chemotherapy

References

- 1. Martínez-Sáez O, Prat A. JCO Oncol Pract. 2021;OP2100172 2. Rugo HS, et al. JAMA Oncol. 2021;7(4):573-584.
- 3. Weisser N. et al. Presented at: American Association for Cancer Research Annual Meeting: April 10-15. May 17-21, 2021. Virtual. Abstract 1005. 4. Hamilton E, et al. Presented at: San Antonio Breast Cancer Society Symposium; December 5-9, 2017; San Antonio, TX. Abstract P5-20-06 5. Meric-Bernstam F, et al. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 15-17, 2021. Virtual. Abstract 164.
- 6. Meric-Bernstam F. et al. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium: January 15-17, 2021, Virtual, Abstract 299. 7. Ku G, et al. Presented at: European Society for Medical Oncology Congress; September 16-21, 2021. Virtual. Abstract 1380P. 8. Clinicaltrials.gov. Accessed September 26. 2021. https://clinicaltrials.gov/ct2/show/NCT02892123

Acknowledgements

We sincerely thank all patients and their families. We thank all the investigators, clinical trial researchers, personnel, and staff who contributed to the trial. ZWI-ZW25-101 trial is sponsored by Zymeworks Inc

jec	ts						
	N	<u>Aedian</u> 7.	PFS, m 3 (3.6,	o (95% NE)	<u>CI)</u>		
					+		
16	18	20	22	24	26	-	
3 (13)	3 (13)	2 (8)	1 (4)	1 (4)	0 (0)		

Copies of this e-Poste obtained through QR codes are for personal use only and may not be reproduced without written permission of the author:

